March 2016 - Volume 26 - Issue 3 - Contributor Index

Alphabetical Search
E
H
I
J
O
Q
R
U
X
Z
Author:

Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)

Lee, Adam M.; Shi, Qian; Alberts, Steven R.; More

Pharmacogenetics and Genomics. 26(3):133-137, March 2016.

Author:
Altman, Russ B.

Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)

Lee, Adam M.; Shi, Qian; Alberts, Steven R.; More

Pharmacogenetics and Genomics. 26(3):133-137, March 2016.

Author:
Boyko, Alexey

The COL1A1 SP1 polymorphism is associated with lower bone mineral density in patients treated with valproic acid

Villegas-Martínez, Irene; de-Miguel-Elízaga, Irene; Carrasco-Torres, Rubén; More

Pharmacogenetics and Genomics. 26(3):126-132, March 2016.

The COL1A1 SP1 polymorphism is associated with lower bone mineral density in patients treated with valproic acid

Villegas-Martínez, Irene; de-Miguel-Elízaga, Irene; Carrasco-Torres, Rubén; More

Pharmacogenetics and Genomics. 26(3):126-132, March 2016.

Author:
Chan, Emily

Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)

Lee, Adam M.; Shi, Qian; Alberts, Steven R.; More

Pharmacogenetics and Genomics. 26(3):133-137, March 2016.

Author:
Cho, Arthur

The COL1A1 SP1 polymorphism is associated with lower bone mineral density in patients treated with valproic acid

Villegas-Martínez, Irene; de-Miguel-Elízaga, Irene; Carrasco-Torres, Rubén; More

Pharmacogenetics and Genomics. 26(3):126-132, March 2016.

Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)

Lee, Adam M.; Shi, Qian; Alberts, Steven R.; More

Pharmacogenetics and Genomics. 26(3):133-137, March 2016.

Author:
Favorova, Olga
Author:
Gill, Sharlene

Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)

Lee, Adam M.; Shi, Qian; Alberts, Steven R.; More

Pharmacogenetics and Genomics. 26(3):133-137, March 2016.

Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)

Lee, Adam M.; Shi, Qian; Alberts, Steven R.; More

Pharmacogenetics and Genomics. 26(3):133-137, March 2016.

Author:
Grothey, Axel

Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)

Lee, Adam M.; Shi, Qian; Alberts, Steven R.; More

Pharmacogenetics and Genomics. 26(3):133-137, March 2016.

Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)

Lee, Adam M.; Shi, Qian; Alberts, Steven R.; More

Pharmacogenetics and Genomics. 26(3):133-137, March 2016.

Author:
Kim, Hye Ryun
Author:
Kim, Joo Hang
Author:
Klein, Teri E.
Author:
Kulakova, Olga
Author:
Lee, Adam M.

Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)

Lee, Adam M.; Shi, Qian; Alberts, Steven R.; More

Pharmacogenetics and Genomics. 26(3):133-137, March 2016.

Author:
Lee, Min Goo
Author:
Lim, Sun Min
Author:
Marras, Carlos

The COL1A1 SP1 polymorphism is associated with lower bone mineral density in patients treated with valproic acid

Villegas-Martínez, Irene; de-Miguel-Elízaga, Irene; Carrasco-Torres, Rubén; More

Pharmacogenetics and Genomics. 26(3):126-132, March 2016.

The COL1A1 SP1 polymorphism is associated with lower bone mineral density in patients treated with valproic acid

Villegas-Martínez, Irene; de-Miguel-Elízaga, Irene; Carrasco-Torres, Rubén; More

Pharmacogenetics and Genomics. 26(3):126-132, March 2016.

The COL1A1 SP1 polymorphism is associated with lower bone mineral density in patients treated with valproic acid

Villegas-Martínez, Irene; de-Miguel-Elízaga, Irene; Carrasco-Torres, Rubén; More

Pharmacogenetics and Genomics. 26(3):126-132, March 2016.

Author:
Nair, Suresh G.

Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)

Lee, Adam M.; Shi, Qian; Alberts, Steven R.; More

Pharmacogenetics and Genomics. 26(3):133-137, March 2016.

Author:
Polite, Blase

Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)

Lee, Adam M.; Shi, Qian; Alberts, Steven R.; More

Pharmacogenetics and Genomics. 26(3):133-137, March 2016.

Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)

Lee, Adam M.; Shi, Qian; Alberts, Steven R.; More

Pharmacogenetics and Genomics. 26(3):133-137, March 2016.

Author:
Shi, Qian

Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)

Lee, Adam M.; Shi, Qian; Alberts, Steven R.; More

Pharmacogenetics and Genomics. 26(3):133-137, March 2016.

Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)

Lee, Adam M.; Shi, Qian; Alberts, Steven R.; More

Pharmacogenetics and Genomics. 26(3):133-137, March 2016.

Author:
Shin, Ho Jung
Author:
Shin, Jae-Gook

Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)

Lee, Adam M.; Shi, Qian; Alberts, Steven R.; More

Pharmacogenetics and Genomics. 26(3):133-137, March 2016.

The COL1A1 SP1 polymorphism is associated with lower bone mineral density in patients treated with valproic acid

Villegas-Martínez, Irene; de-Miguel-Elízaga, Irene; Carrasco-Torres, Rubén; More

Pharmacogenetics and Genomics. 26(3):126-132, March 2016.

The COL1A1 SP1 polymorphism is associated with lower bone mineral density in patients treated with valproic acid

Villegas-Martínez, Irene; de-Miguel-Elízaga, Irene; Carrasco-Torres, Rubén; More

Pharmacogenetics and Genomics. 26(3):126-132, March 2016.

The COL1A1 SP1 polymorphism is associated with lower bone mineral density in patients treated with valproic acid

Villegas-Martínez, Irene; de-Miguel-Elízaga, Irene; Carrasco-Torres, Rubén; More

Pharmacogenetics and Genomics. 26(3):126-132, March 2016.

Show: